T3D Therapeutics

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2/3
PPAR delta/gammaSmall molecule
Alzheimer's Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2031 (1)
April 2031 (1)
T3D-959Phase 2/3Alzheimer's Disease
Est. primary completion 2031-04 · NCT06964230 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 November 2023Topline resultT3D-959PIONEER Phase 2 (NCT04251182) top-line results presented at CTAD 2023
T3D Therapeutics · Source ↗

Financial reports

No financial reports recorded.